Firebrick Pharma 配当と自社株買い

配当金基準チェック /06

Firebrick Pharma配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-7.2%

バイバック利回り

総株主利回り	-7.2%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

決済の安定と成長

配当データの取得

安定した配当: FREの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: FREの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Firebrick Pharma 配当利回り対市場

FRE 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (FRE)	n/a
市場下位25% (AU)	2.6%
市場トップ25% (AU)	6.1%
業界平均 (Pharmaceuticals)	2.2%
アナリスト予想 (FRE) (最長3年)	n/a

注目すべき配当: FREは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: FREは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: FREの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: FREが配当金を報告していないため、配当金の持続可能性を計算できません。

Firebrick Pharma 配当と自社株買い

配当金基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024

Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.

Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)

Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.

New minor risk - Share price stability

Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold

Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)

Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation

Firebrick Update on Administrative Appeals Tribunal Process

Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

No independent directors

Firebrick Pharma Limited Announces CFO Changes

Firebrick Pharma Limited Provides Update on its Phase 3 Clinical Trial of Nasodine Nasal Spray in Treatment of Common Cold

Rebrick Pharma Limited Announces Nasodine Patent Granted in Singapore

Firebrick Pharma Limited, Annual General Meeting, Nov 23, 2022

Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Firebrick Appoints Richard Treagus as Director

Firebrick Appoints Richard Treagus as Director

Firebrick Pharma Limited Starts Phase 3 Common Cold Trial

No independent directors

Firebrick Pharma Limited Starts COVID-19 Trial of Nasodine

Firebrick Pharma Limited Announces the Results of in Vitro Studies of Nasodine® Nasal Spray

Firebrick Pharma Limited Announces That Its Planned Clinical Trial of Nasodine Nasal Spray (Povidone-Iodine 0.5%) in Covid-19 Patients in South Africa, Had Received Approval to Proceed from the South African Health Products Regulatory Authority

No independent directors

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

Firebrick Pharma 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Firebrick Pharma Limited, Annual General Meeting, Nov 27, 2024

Firebrick Pharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1587 million.

Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.04 loss in FY 2023)

Firebrick Pharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.

New minor risk - Share price stability

Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold

Full year 2023 earnings released: AU$0.04 loss per share (vs AU$0.033 loss in FY 2022)

Here's Why We're Watching Firebrick Pharma's (ASX:FRE) Cash Burn Situation

Firebrick Update on Administrative Appeals Tribunal Process

Firebrick Pharma Limited, Annual General Meeting, Jun 20, 2023

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

We Think Firebrick Pharma (ASX:FRE) Needs To Drive Business Growth Carefully

No independent directors

Firebrick Pharma Limited Announces CFO Changes

Firebrick Pharma Limited Provides Update on its Phase 3 Clinical Trial of Nasodine Nasal Spray in Treatment of Common Cold

Rebrick Pharma Limited Announces Nasodine Patent Granted in Singapore

Firebrick Pharma Limited, Annual General Meeting, Nov 23, 2022

Companies Like Firebrick Pharma (ASX:FRE) Are In A Position To Invest In Growth

Firebrick Appoints Richard Treagus as Director

Firebrick Appoints Richard Treagus as Director

Firebrick Pharma Limited Starts Phase 3 Common Cold Trial

No independent directors

Firebrick Pharma Limited Starts COVID-19 Trial of Nasodine

Firebrick Pharma Limited Announces the Results of in Vitro Studies of Nasodine® Nasal Spray

Firebrick Pharma Limited Announces That Its Planned Clinical Trial of Nasodine Nasal Spray (Povidone-Iodine 0.5%) in Covid-19 Patients in South Africa, Had Received Approval to Proceed from the South African Health Products Regulatory Authority

No independent directors

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06